|
(MoneyNewsWire.Net, May 03, 2018 ) The Asia-Pacific Multiple Myeloma Therapeutics Market was worth $1.37 billion in 2016 and estimated to be growing at a CAGR of 5.5%, to reach $1.79 billion by 2021. Due to increase in geriatric population in the countries like China and India, Asia-Pacific is expected to witness highest growth rate in the forecast period.
Multiple myeloma remains comparatively rare, it is a deceptive disease and patients typically deplete treatment alternatives. Myeloma and MGUS are twice as common in blacks paralleled with whites and marginally more common in males than females.
Browse market data tables and in-depth TOC of the Asia-Pacific Multiple Myeloma Therapeutics Market to 2021 @ https://www.marketdataforecast.com/market-reports/asia-pacific-multiple-myeloma-therapeutics-market-861/
The growth of multiple myeloma therapeutics market will largely be driven by the development of novel therapeutics that have considerably improved clinical outcomes through all stages of the disease, as well as the absence of standard competition in countries like China, Japan and Australia. Evolving multiple myeloma therapies are probable to offer choices in the lapsed or refractory disease setting, in both the second and third lines of treatment, additionally enhancing APAC market growth. High cost associated with treatment of the disease is expected to restrain the market growth.
The Asia-Pacific Multiple Myeloma Therapeutics Market is segmented on the basis of Treatment Type into Chemotherapy which is further segmented into Anthracycline Antibiotic (Melphalan (Alkeran), Liposomal doxorubicin (Doxil)) and Alkylating agent (Doxorubicin (Adriamycin), Cyclophosphamide (Neosar), Vincristine (Oncovin), Carmustine (BiCNU)) and Targeted Therapy ( Proteasome Inhibitor (Bortezomib (Velcade), Carfilzomib (Kyprolis)), by Drug Type into Corticosteroids (Dexamethasone (Decadron), Prednisone (Deltasone/Orasone)) and Immunomodulatory Agents (Thalidomide (Thalomid), Lenalidomide (Revlimid), Arsenic trioxide (Trisenox), Plerixafor (Mozobil)). With the advancement in technology targeted therapy is on a high growth due to its advantages over chemotherapy such as lesser side effects.
Free sample of the report is available @ https://www.marketdataforecast.com/market-reports/asia-pacific-multiple-myeloma-therapeutics-market-861/request-sample
Based on geography the market is analysed under various regions namely, China, India, Japan, South Korea and Australia. Australia and Japan are most likely to increase in the forecast period due to rising number of myeloma cases in the region.
Some of the key contributors in the industry include AB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC. , ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc. ,Teva Pharmaceutical Industries Ltd. ,TG Therapeutics Inc. and Johnson and Johnson.
Inquire before buying @ https://www.marketdataforecast.com/market-reports/asia-pacific-multiple-myeloma-therapeutics-market-861/inquire
The scope of the report provides:
The evaluation of the current market for your product or services and the future implications of the market
Addresses the opportunities by better understanding the market through size estimates and growth rate analysis to forecast the market for the future
Extensive segmentation to understand the dynamics of market at a very granular level by splitting down the market to the smallest segment
Addresses the key market dynamics involving the drivers, restraints and challenges with an aim of providing insights for gaining market share
The factors responsible for the shaping of the industry as it is as a result of competitive environment is analyzed through Porters Five Forces
The effects of political, economic, social, technological, legal and environmental factors on the industry is analyzed through PESTLE analysis to better understand the aspects of strategic management required to comply with the exogenous and endogenous factors
Strategic evaluation of the key players to gain insights of their performance allowing access to their product portfolio, financial performance and the strengths of their business strategic developments
Comparative study of the firms across the industry measuring their performances based on market share and recent activities in order to achieve competitive intelligence
Equip you with the information providing with the investment opportunities in the industry
Looking for more? If you are in need of a specific research study, we have an expertise in undertaking a customized study and will aid to meet your research requirement to the fullest.
Order your copy of the report: https://www.marketdataforecast.com/cart/buy-now/asia-pacific-multiple-myeloma-therapeutics-market-861/
About Us:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.
Contact:
Abhishek Shukla
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail:abhishek@marketdataforecast.com
Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/
Follow us @ https://in.linkedin.com/company/market-data-forecast
Market Data Forecast.
Abhishek Shukla
+1-888-702-9626
abhishek@marketdataforecast.com
Source: EmailWire.Com 
|
